- Home
- GANX vs ALGS Comparison
GANX vs ALGS Comparison
Compare GANX & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- ALGS
- Stock Information
- Founded
- GANX 2017
- ALGS 2018
- Country
- GANX United States
- ALGS United States
- Employees
- GANX N/A
- ALGS N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- GANX Health Care
- ALGS Health Care
- Exchange
- GANX Nasdaq
- ALGS Nasdaq
- Market Cap
- GANX 53.8M
- ALGS 50.4M
- IPO Year
- GANX 2021
- ALGS 2020
- Fundamental
- Price
- GANX $1.72
- ALGS $8.46
- Analyst Decision
- GANX Strong Buy
- ALGS Strong Buy
- Analyst Count
- GANX 5
- ALGS 1
- Target Price
- GANX $8.20
- ALGS $70.00
- AVG Volume (30 Days)
- GANX 299.5K
- ALGS 99.2K
- Earning Date
- GANX 08-07-2025
- ALGS 08-05-2025
- Dividend Yield
- GANX N/A
- ALGS N/A
- EPS Growth
- GANX N/A
- ALGS N/A
- EPS
- GANX N/A
- ALGS N/A
- Revenue
- GANX N/A
- ALGS $3,270,000.00
- Revenue This Year
- GANX N/A
- ALGS N/A
- Revenue Next Year
- GANX N/A
- ALGS $51.55
- P/E Ratio
- GANX N/A
- ALGS N/A
- Revenue Growth
- GANX N/A
- ALGS N/A
- 52 Week Low
- GANX $0.89
- ALGS $3.76
- 52 Week High
- GANX $3.19
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- GANX 49.29
- ALGS 63.36
- Support Level
- GANX $1.55
- ALGS $6.82
- Resistance Level
- GANX $1.79
- ALGS $9.10
- Average True Range (ATR)
- GANX 0.16
- ALGS 0.75
- MACD
- GANX -0.00
- ALGS 0.08
- Stochastic Oscillator
- GANX 44.53
- ALGS 86.38
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.